ClinicalTrials.gg
CompletedNCT07931027Updated Nov 12, 2026

Painless Digestive Endoscopy in the Elderly: Hypoxemia Evolution and Risk Stratification

An observational study in Hypoxemia During Surgery, sponsored by Chinese PLA General Hospital. Completed at 1 site in China. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Chinese PLA General Hospital · Observational

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
640
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 96 studies in Hypoxia with a site in China — 43 open to participants now, 44 under way, none of them phase 3. Hypoxia · China.

Enrollment
5th of 18
640 · median 120
Started
2022
with 8 others
Observational
18 of 96
4 open now
Registered
95th of 96
by date
Lead sponsor
4 of 96
Chinese PLA General Hospital

Among the 96 studies in Hypoxia with a site in China, this one is the 5th largest by enrollment of the 18 observational ones that give a count, is one of 9 that started in 2022, is one of 18 observational ones, and was the 95th registered.

Hypoxia

1,078 studies on the registry are indexed under Hypoxia; 214 are open to participants now.

Browse Hypoxia studies →

Open to participants now

43 of the 96 studies in Hypoxia with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 126 Hypoxia studies recruiting now, 53 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Hypoxia with a site in China, or all of them as a file.
02

Study summary

The goal of this prospective observational cohort study is to identify independent risk factors for subclinical and clinical hypoxemia and factors promoting progression from subclinical to clinical hypoxemia in elderly patients undergoing painless digestive endoscopy under propofol-etomidate sedation.

The main questions it aims to answer are:

  • What are the independent risk factors for subclinical hypoxemia (90%≤SpO₂\<95%)?
  • What are the independent risk factors for clinical hypoxemia (SpO₂\<90%)?
  • Among patients with subclinical hypoxemia, what factors promote progression to clinical hypoxemia?

Researchers will compare three groups stratified by lowest intraoperative SpO₂-normal control (SpO₂≥95%, n=382), subclinical hypoxemia (90%≤SpO₂\<95%, n=181), and clinical hypoxemia (SpO₂\<90%, n=77)-to see whether factors such as sex, BMI, snoring, hypertension, and anesthesia duration are associated with hypoxemia severity and progression.

Participants will:

  • Undergo painless gastrointestinal endoscopy.
  • Receive propofol combined with etomidate sedation.
  • Have intraoperative SpO₂ monitored.
  • Have relevant clinical data recorded.
03

Conditions studied

  • Hypoxemia During Surgery

Browse trials for

Keywords

  • hypoxemia
  • subclinical hypoxemia
  • risk factors
  • aged
  • gastrointestinal endoscopy
  • sedation
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

It also included all patients who underwent painless gastroscopy and colonoscopy at the Digestive Endoscopy Center of the First Medical Center of the PLA General Hospital from November 1, 2022 to February 28, 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 65 years;
  • (ASA) classification of grade I or II
  • (BMI) within the range of 18.5 - 28.0 kg/m²
  • Plans to undergo gastroscopy and colonoscopy consecutively under the same intravenous anesthesia and sedation (gastroscopy first, then colonoscopy).

Exclusion criteria

Exclusion Criteria:

  • Baseline SpO₂ \< 95% when breathing air at rest
  • Known active malignant tumors
  • Central nervous system diseases affecting respiratory drive function
  • Expected difficult airway (Mallampati grade IV or documented history of difficult intubation)
  • Refusal to sign the written form
  • Digestive tract malignant tumors found during endoscopy (assessed after enrollment)
  • Insufficient bowel preparation preventing completion of colonoscopy (assessed after enrollment)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
640 participants (actual)
Patient registry
No

Groups and cohorts

  • Clinical Hypoxaemia Group

    SpO₂ \< 90%

  • Subclinical Hypoxemia Group

    SpO₂ ≥ 90% and \< 95%

    Behavioral: oxygen therapy via face mask

  • Normal Control Group

    SpO₂ ≥ 95%

Interventions

  • Behavioraloxygen therapy via face mask

    oxygen therapy via face mask

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Episode of Subclinical Hypoxaemia (90% ≤ SpO₂ < 95% for ≥10 Seconds)During sedated gastrointestinal endoscopy

    Subclinical hypoxemia was defined as pulse oximetry-derived SpO₂ decreasing to 90% ≤ SpO₂ \< 95% and sustained for at least 10 seconds at any point during sedated gastrointestinal endoscopy . SpO₂ was monitored continuously throughout the procedure. The outcome was the proportion of participants who experienced at least one qualifying episode; each participant was counted only once regardless of the number of episodes. Results were reported as the number and percentage of participants (n/N, %) in each group.

    Time frame: Periprocedural

  2. Percentage of Participants With at Least One Episode of clinical Hypoxemia ( <90% for ≥10 Seconds)During sedated gastrointestinal endoscopy

    clinical hypoxemia was defined as SpO₂ decreasing to \<90% for ≥10 seconds at any point during sedated gastrointestinal endoscopy . SpO₂ was monitored continuously throughout the procedure. The outcome was the proportion of participants who experienced at least one qualifying episode; each participant was counted only once regardless of the number of episodes. Results were reported as the number and percentage of participants (n/N, %) in each group.

    Time frame: Periprocedural

07

Study locations

1 site
  • Medtronic 20p
    Beijing, Beijing Municipality 100853, China
08

References and documents

Publications

  • Li XM, Hao SQ, Qi XR, Hao DD, Li Y, An LX. Effects of low-dose esketamine on hypoxemia during gastroscopy in patients with moderate-to-high risk obstructive sleep apnea: protocol for a prospective, randomized, controlled trial. Trials. 2025 Sep 26;26(1):364. doi: 10.1186/s13063-025-09098-w. PubMed 41013777 ↗
  • Liu F, Zhang C, Wang X, Qi B, Zheng L, Zhao Y, Yu W. Efficacy of high-flow nasal oxygen in preventing hypoxia during Gastrointestinal endoscopy: a retrospective cohort study. BMC Anesthesiol. 2025 Jun 3;25(1):287. doi: 10.1186/s12871-025-03155-2. PubMed 40461980 ↗
  • Qi XR, Sun JY, An LX, Zhang K, Xue FS. Effects of intravenous lidocaine on hypoxemia induced by propofol-based sedation for gastrointestinal endoscopy procedures: study protocol for a prospective, randomized, controlled trial. Trials. 2022 Sep 24;23(1):800. doi: 10.1186/s13063-022-06719-6. PubMed 36153625 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Feb 2024, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2026
First posted
Nov 12, 2026
StartActual
Nov 1, 2022
Primary completionActual
Feb 28, 2024
CompletionActual
Feb 28, 2024
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07931027
Responsible party
Peiqi Wang (Principal Investigator, Chinese PLA General Hospital) — Principal investigator
First posted
Nov 12, 2026
Start date
Nov 1, 2022
Primary completion
Feb 28, 2024
Completion
Feb 28, 2024
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion